Feline Immune-Mediated Disease: Diagnostic Approach and Management

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Feline immune-mediated diseases are challenging due to nonspecific signs and species-specific immunologic differences, necessitating a systematic diagnostic approach prioritizing pattern recognition and exclusion of infectious mimics before immunosuppression.
• Key exclusions in the diagnostic workup include feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), and hemotropic mycoplasmosis, as these infectious agents can mimic immune-mediated conditions and immunosuppression can exacerbate them.
• The diagnostic algorithm progresses from a minimum database (CBC, biochemistry, urinalysis, retroviral testing) to syndrome-specific testing (e.g., synovial fluid analysis for polyarthritis, skin biopsies for dermatologic disease) and, when indicated, bone marrow evaluation.
• Common clinical presentations include anemia, thrombocytopenia, polyarthritis (often with fever and lethargy rather than overt joint swelling), and skin lesions, with specific diagnostic tests like blood smear review, PCR for hemoplasmas, and histopathology being crucial for confirmation.
• Glucocorticoids are the first-line therapeutic agents, with adjunctive immunosuppressants selected based on disease severity and response, and monitoring must include serial CBCs, clinical assessment, and surveillance for adverse effects like iatrogenic diabetes mellitus or secondary infections.
• Response to therapy should not be the sole diagnostic criterion, as non-specific anti-inflammatory effects of glucocorticoids can mask underlying conditions; diagnosis relies on integrating clinical findings, laboratory data, and exclusion of differential diagnoses.

Immune-mediated disease in cats presents a diagnostic challenge that differs substantially from the canine experience. Feline patients frequently display nonspecific clinical signs, possess species-specific hematologic and immunologic peculiarities, and develop disease variants that do not map cleanly onto canine paradigms. This article provides a systematic diagnostic framework for the practicing veterinarian evaluating a cat for suspected immune-mediated disease, with emphasis on clinical reasoning, test selection, and interpretation of results. It covers the conceptual basis of immune dysregulation, common clinical presentations, diagnostic algorithms, and therapeutic principles, while excluding detailed coverage of specific diseases addressed in dedicated references.

The clinical question this article answers is practical: when a cat presents with signs compatible with immune-mediated disease, how should the clinician proceed? The approach prioritizes pattern recognition, exclusion of differential diagnoses, and confirmation of immunopathologic mechanisms before committing to immunosuppressive therapy. This is particularly important in cats, where infectious diseases frequently mimic immune-mediated conditions and where the consequences of inappropriate immunosuppression can be severe.

At a Glance

Conceptual Foundations of Feline Immune Dysregulation

Immune-mediated disease arises from loss of self-tolerance, leading to immune effector mechanisms directed against host tissues. The immunopathogenesis involves complex interactions between genetic susceptibility and environmental triggers. Comparative genomic studies in human autoimmune disease have demonstrated that susceptibility loci cluster nonrandomly across multiple conditions, suggesting shared immunoregulatory pathways Clustering of non-MHC susceptibility loci in human autoimmune diseases. This clustering implies that clinically distinct immune-mediated diseases may share common genetic underpinnings, a concept that informs the feline approach: a cat with one immune-mediated condition may be predisposed to others, and a family history of autoimmunity may increase suspicion.

The effector mechanisms of tissue damage in immune-mediated disease include type II hypersensitivity (antibody-mediated cytotoxicity), type III hypersensitivity (immune complex deposition), and type IV hypersensitivity (T cell-mediated injury). The T helper 17 (Th17) pathway and its signature cytokine IL-17A have emerged as central mediators in multiple autoimmune and inflammatory conditions, including psoriasis and rheumatoid arthritis in humans Th17 cells and IL-17A in immunopathogenesis and immunotherapeutics. While feline-specific data are limited, the conservation of these pathways across mammalian species supports their relevance to feline immune-mediated disease. Recognition of these mechanisms guides both diagnostic testing and therapeutic selection, as different effector pathways may respond differently to immunomodulatory agents.

The hygiene hypothesis, originally formulated from human epidemiologic observations, proposes that reduced exposure to helminths and other organizms in industrialized environments has contributed to rising autoimmune disease prevalence. Helminth infections modulate host immunity by promoting regulatory pathways, including IL-10 and TGF-beta production and regulatory T cell induction Helminth-host immunological interactions in immune-mediated disease prevention. The relevance to feline medicine is indirect but conceptually useful: environmental factors, including infectious exposure history, may influence immune regulation in individual cats, and the absence of prior infectious challenges does not exclude immune-mediated disease.

The Feline Immunologic Context

Feline immune responses differ from canine responses in ways that affect both disease expression and diagnostic interpretation. Cats exhibit a more restricted major histocompatibility complex diversity than dogs, which may influence susceptibility patterns to immune-mediated disease. Feline immunoglobulin subclasses and complement pathways show species-specific characteriztics that can affect serologic test performance. Clinicians should therefore avoid extrapolating canine reference intervals and assay cutoffs to feline patients without validation.

The retrovirus status of any cat with suspected immune-mediated disease must be established early in the diagnostic process. Feline leukemia virus and feline immunodeficiency virus infections can produce clinical syndromes that mimic primary immune-mediated disease, including anemia, thrombocytopenia, and lymphadenopathy. Retroviral testing should be performed in all suspected cases before immunosuppressive therapy is initiated, as immunosuppression in a retrovirus-infected cat can accelerate disease progression. The MSD Veterinary Manual provides species-specific guidance on retroviral testing and interpretation.

Pathophysiology of Common Feline Immune-Mediated Syndromes

The immune-mediated syndromes most frequently encountered in feline practice include immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, immune-mediated polyarthritis, and immune-mediated skin disease. Each involves distinct effector mechanisms and presents with characteriztic clinical and laboratory findings.

Immune-mediated hemolytic anemia in cats results from antibody or complement-mediated destruction of erythrocytes. Primary (idiopathic) forms are less common in cats than in dogs, and secondary causes, particularly hemotropic mycoplasmosis and retroviral infection, must be rigorously excluded. Feline erythrocytes lack the surface antigens that are common targets in canine immune-mediated hemolytic anemia, and the direct agglutination test may be less sensitive in cats. The presence of spherocytes, a hallmark finding in dogs, is less reliable in cats because feline erythrocytes are smaller and spherocyte identification is more challenging.

Immune-mediated thrombocytopenia in cats presents with petechiation, ecchymoses, and mucosal bleeding. Primary immune-mediated thrombocytopenia is uncommon in cats, and secondary causes including infectious agents and drug reactions should be investigated. Platelet count confirmation by blood smear examination is essential, as automated counts may be falsely decreased due to platelet clumping, a common artifact in feline blood samples.

Immune-mediated polyarthritis in cats typically presents with fever, lethargy, and reluctance to move instead of obvious joint swelling. Erosive and nonerosive forms exist, and infectious causes, particularly calicivirus and Mycoplasma species, must be excluded through synovial fluid analysis and culture. The ACVIM consensus statements provide expert guidance on diagnostic criteria for immune-mediated arthropathies in companion animals.

Immune-mediated skin disease in cats encompasses several distinct entities, including pemphigus foliaceus, the most common autoimmune skin disease in this species, and erythema multiforme. Diagnosis relies on characteriztic histopathologic findings from skin biopsy, with direct immunofluorescence serving as an adjunct in selected cases. The distribution of lesions, particularly the involvement of paw pads, nasal planum, and periocular skin in pemphigus foliaceus, provides important clinical clues.

Diagnostic Reasoning Framework

The diagnostic approach to suspected feline immune-mediated disease follows a structured sequence. The first step is characterization of the clinical syndrome through history, physical examination, and minimum database testing. The second step is exclusion of infectious, neoplastic, and toxic differential diagnoses. The third step is confirmation of immune-mediated mechanisms through specific testing. The fourth step is assessment of disease severity and comorbid conditions to guide therapeutic decisions.

The minimum database includes complete blood count, serum biochemistry panel, urinalysis, and retroviral testing. Additional testing is guided by the presenting syndrome. For suspected immune-mediated hemolytic anemia, this includes blood smear evaluation for hemotropic mycoplasmas, saline agglutination testing, and Coombs testing where available. For suspected immune-mediated polyarthritis, synovial fluid analysis with cytology and culture is essential. For suspected immune-mediated skin disease, multiple skin biopsies from representative lesions are required.

The American Veterinary Medical Association practice resources provide guidance on professional standards for diagnostic testing and client communication that apply to the workup of suspected immune-mediated disease. The World Organization for Animal Health terrestrial animal health standards address surveillance and reporting considerations relevant when infectious differentials are under consideration, particularly those with zoonotic potential.

A critical principle in feline immune-mediated disease diagnosis is that response to therapy should not be used as the sole diagnostic criterion. Glucocorticoids produce clinical improvement in many inflammatory and neoplastic conditions through nonspecific anti-inflammatory effects. Conversely, some cats with confirmed immune-mediated disease respond incompletely to initial therapy, requiring dose adjustment or adjunctive agents. The diagnosis should rest on the integration of clinical findings, laboratory data, and exclusion of differential diagnoses, not on therapeutic response alone.

Clinical Assessment Sequence

The diagnostic approach begins with a complete history and physical examination, followed by staged laboratory testing. The sequence matters because immune-mediated disease in cats is often a diagnosis of exclusion, and the cost of missing an infectious or neoplastic mimic is substantial.

Historical features that raise suspicion include recurrent or migratory signs, multi-system involvement, poor response to empirical antimicrobial therapy, and signalment-specific patterns. Breed predisposition is less well defined in cats than in dogs, but the clinician should still record breed, age, and sex, as these influence the differential list. Indoor-outdoor status, vaccination history, retroviral status, and current medications, including topical parasiticides and glucocorticoids, are essential data points.

Physical examination should be systematic and repeated. Fever, peripheral lymphadenomegaly, pallor, icterus, skin lesions, joint effusion or pain on manipulation, and oral ulceration are common findings. The presence of fever with polyarthritis in a young adult cat should prompt consideration of immune-mediated polyarthritis, whereas fever with cytopenias in a middle-aged cat raises concern for immune-mediated hemolytic anemia or immune-mediated thrombocytopenia. Neurologic signs, uveitis, and renomegaly broaden the differential to include infectious causes such as feline infectious peritonitis, toxoplasmosis, and fungal disease.

Minimum Database and Staging

A minimum database should include complete blood count with manual blood smear review, serum biochemistry profile, urinalysis with sediment examination, and retroviral testing for feline leukemia virus antigen and feline immunodeficiency virus antibody. Blood smear review is non-negotiable. It detects spherocytes, Heinz bodies, polychromasia, nucleated red blood cells, platelet clumps, and infectious organizms such as Mycoplasma hemofelis or Cytauxzoon felis.

The biochemistry profile identifies azotemia, hyperglobulinemia, hypoalbuminemia, and elevated liver enzyme activity, each of which redirects the investigation. Hyperglobulinemia with a polyclonal pattern supports chronic inflammation or infection, whereas a monoclonal spike raises concern for neoplasia. Urinalysis may reveal proteinuria, hematuria, or casts, prompting urine protein-to-creatinine ratio and urine culture.

Imaging is indicated when physical examination or laboratory findings suggest thoracic or abdominal disease. Thoracic radiographs detect mediastinal masses, pulmonary infiltrates, and pleural effusion. Abdominal ultrasound evaluates liver, spleen, kidneys, and lymph nodes, and guides fine-needle aspiration or biopsy when cytopenias or organomegaly are present. Echocardiography is reserved for cats with murmurs or suspected infective endocarditis.

Differential Prioritization Framework

The differential list for suspected immune-mediated disease in cats is broad, and prioritization depends on the dominant clinical syndrome. The table below provides a syndrome-based framework.

The framework is not exhaustive. Cats may present with overlapping syndromes, and the clinician must adapt the sequence to the individual patient. For example, a cat with IMHA and concurrent thrombocytopenia may have Evans syndrome, but the same combination can occur with hemoplasmosis, sepsis, or disseminated neoplasia.

Diagnostic Testing Algorithm

The testing algorithm proceeds from non-invasive to invasive, and from broad to specific. Step one is the minimum database described above. Step two is directed testing based on the dominant syndrome. Step three is advanced diagnostics when the initial workup is unrewarding or when the patient deteriorates.

For suspected immune-mediated hemolytic anemia, the diagnostic sequence includes blood smear evaluation, saline agglutination testing, and Coombs testing. Saline agglutination is performed by mixing one drop of blood with several drops of saline and observing for macroscopic agglutination after washing. A positive saline agglutination test supports a diagnosis of IMHA, but it does not distinguish primary from secondary disease. Coombs testing detects antibody or complement on red blood cells, but false negatives occur with prior glucocorticoid administration and with low antibody density. PCR for hemoplasmas is indicated in cats with regenerative anemia, particularly those with outdoor access or a history of flea infestation.

For suspected immune-mediated polyarthritis, synovial fluid analysis is the pivotal test. Arthrocentesis should be performed on multiple joints, including carpi, tarsi, and stifles, even if only one joint is visibly swollen. Fluid should be collected into EDTA for cytology and into a sterile tube for culture. Neutrophilic inflammation with a predominance of non-degenerate neutrophils supports immune-mediated disease, whereas degenerate neutrophils with intracellular bacteria support septic arthritis. Culture is essential because negative cytology does not exclude infection.

For suspected immune-mediated skin disease, skin biopsy is the diagnostic standard. Multiple punch biopsies should be taken from early lesions, including intact pustules and vesicles, and submitted in formalin for histopathology. A separate sample should be submitted for bacterial and fungal culture. Direct impression smears of intact pustules may reveal acantholytic keratinocytes, which support pemphigus foliaceus, but histopathology is required for confirmation.

Bone marrow aspiration is indicated when cytopenias are non-regenerative, when more than one cell line is affected, or when the patient fails to respond to immunosuppressive therapy. Bone marrow cytology distinguishes immune-mediated destruction from primary bone marrow disease, including myelodysplasia, lymphoma, and aplastic anemia. The sample should be evaluated by a clinical pathologist, and the clinician should correlate cytologic findings with peripheral blood counts.

Monitoring and Documentation

Monitoring parameters depend on the syndrome and the drugs used. For cats receiving glucocorticoids, body weight, appetite, blood glucose, and urine glucose should be assessed at each recheck. Glucocorticoid-induced diabetes mellitus is a recognized complication in cats, and insulin therapy may be required. For cats receiving chlorambucil or other cytotoxic agents, complete blood counts should be performed every two to four weeks initially, with dose adjustment based on neutrophil and platelet counts.

Disease-specific monitoring includes packed cell volume and reticulocyte count for IMHA, synovial fluid analysis for polyarthritis, and skin lesion scoring for dermatologic disease. The clinician should document the response to therapy using objective parameters, such as the packed cell volume trend, the number of affected joints, or the percentage of body surface area affected by skin lesions. Photographs are useful for dermatologic cases and should be stored in the medical record.

Documentation should include the diagnostic tests performed, the results, the rationale for the diagnosis, the treatment plan, and the monitoring schedule. The medical record should also note any adverse drug reactions and the date and dose of each medication administered. This documentation supports continuity of care and provides a basis for adjusting therapy if the patient relapses.

The evidence base for feline immune-mediated disease management is less robust than for canine disease. Much of the therapeutic guidance is extrapolated from canine medicine, and the clinician should acknowledge this uncertainty when discussing prognosis with the owner. Published reviews of immunomodulatory drug use in canine immune-mediated disease provide a framework for drug selection, but feline-specific pharmacokinetic and safety data are limited, and current formulary references must be consulted before prescribing any immunosuppressive agent.

Recognized Complications and Failure Modes

The principal complications of feline immune-mediated disease arise from the disease process itself, from immunosuppressive therapy, or from diagnostic delay. Thromboembolism, particularly aortic thromboembolism, is the most feared complication of feline immune-mediated hemolytic anemia and can occur before or during treatment. Early detection relies on serial hematocrit measurement, careful monitoring of hindlimb perfusion, and attention to acute onset of paresis, vocalisation, or hypothermia. Thoracic radiography and point-of-care ultrasound may identify pulmonary thromboembolism in dyspnoeic patients.

Infection is the dominant treatment-related complication. Glucocorticoid and adjunctive immunosuppressant use predisposes cats to bacterial upper respiratory infection, dermatophytosis, and opportunistic urinary tract infection. Serial physical examination, urine culture at each recheck, and prompt investigation of new respiratory signs allow early intervention. Feline leukemia virus and feline immunodeficiency virus status should be confirmed before starting immunosuppression, as retroviral infection alters both prognosis and drug selection.

Drug-specific toxicities require structured monitoring. Azathioprine can cause severe myelosuppression and hepatotoxicity in cats, and its use is controversial in this species. Ciclosporin may induce gingival hyperplasia or gastrointestinal signs. Mycophenolate mofetil can produce anorexia and diarrhea. Serial complete blood counts, biochemistry panels, and therapeutic drug monitoring where available permit dose adjustment before irreversible injury occurs.

Common Diagnostic Errors and Corrective Actions

The most frequent error is treating a presumptive immune-mediated diagnosis before excluding infectious mimics. Cats with mycoplasma hemofelis infection, feline infectious peritonitis, or toxoplasmosis can present with anemia, fever, or polyarthritis that resembles primary immune-mediated disease. The corrective action is disciplined adherence to the diagnostic algorithm: retroviral testing, blood smear review, and appropriate pathogen testing before immunosuppression begins.

A second error is overinterpreting a positive antinuclear antibody titre. Low-titre positivity occurs in chronic infection and neoplasia, and the test supports but does not confirm immune-mediated disease. The corrective action is to interpret serology only in the context of compatible clinical signs and histopathology.

A third error is failure to distinguish regenerative from non-regenerative immune-mediated anemia. Pure red cell aplasia and precursor-directed immune-mediated anemia produce non-regenerative anemia with a low reticulocyte count, and these require bone marrow evaluation instead of a standard IMHA protocol. The corrective action is to perform reticulocyte counting on every anemic cat and to progress to bone marrow cytology when regeneration is absent.

Limitations of Current Evidence

The feline immunology literature is less developed than the canine equivalent. Most therapeutic protocols are extrapolated from canine studies or from human medicine, and prospective randomised trials in cats are scarce. The review of immunomodulatory drugs in canine immune-mediated disease illustrates the evidence base available for extrapolation, but direct feline validation is often lacking. Expert opinion differs on the choice of first-line adjunctive agent, the duration of maintenance therapy, and the value of combination protocols in feline patients.

The role of the microbiome and environmental exposure in feline immune dysregulation remains speculative. Human and rodent data suggest that helminth exposure modulates regulatory pathways and may protect against immune-mediated disease, as reviewed in work on helminth-host immunological interactions, but comparable feline studies are absent. Clinicians should therefore avoid making management recommendations based on these mechanisms.

Referral and Escalation Criteria

Referral to a specialist is warranted when the diagnosis remains uncertain after complete staging, when the patient fails to respond to first-line therapy within 7 to 14 days, when glucocorticoid-sparing agents are required but the clinician has limited experience with them, or when bone marrow biopsy, advanced imaging, or complex cytology is needed. Specialist consultation is also appropriate for recurrent disease, for suspected paraneoplastic immune-mediated syndromes, and for cats requiring prolonged combination immunosuppression.

Laboratory involvement extends beyond routine hematology and biochemistry. Flow cytometry, immunohistochemistry, and clonality testing may be required to distinguish inflammatory from neoplastic infiltrates. The ACVIM consensus statements provide structured guidance on diagnostic thresholds and monitoring intervals for immune-mediated conditions.

Regulatory reporting is rarely required for feline immune-mediated disease, but clinicians should be aware that some infectious mimics are reportable. The WOAH terrestrial animal health standards define reporting obligations for diseases such as feline rabies, and local veterinary authorities should be contacted when a notifiable infectious differential is suspected. The AVMA practice resources offer additional guidance on professional obligations and documentation standards.

Frequently Asked Questions

How should I proceed when advanced diagnostics such as flow cytometry or immunohistochemistry are unavailable?

Begin treatment based on a thorough clinical assessment, complete blood count, biochemistry profile, urinalysis, and imaging. These tests often provide sufficient supportive evidence for a presumptive diagnosis. Serology for infectious diseases remains essential, as positive results may redirect therapy entirely. If a corticosteroid trial is elected, document baseline parameters and recheck within 7 to 14 days. A measurable response supports the diagnosis, while deterioration or lack of response warrants reconsideration. Referral for specialized testing may be appropriate when clinical signs are atypical, when response is incomplete, or when the client requests diagnostic certainty before committing to long-term immunosuppression. The MSD Veterinary Manual provides guidance on interpreting routine laboratory data in suspected immune-mediated disease.

What are the realistic cost expectations for diagnosing and managing a suspected immune-mediated condition in a cat?

Diagnostic costs vary widely by region and practice setting. A minimum database with infectious disease screening typically represents a moderate expense, while advanced imaging, bone marrow evaluation, or referral-level testing increases costs substantially. Long-term management includes repeated laboratory monitoring, medication costs, and potential hospitalization for complications. Discuss a tiered diagnostic and treatment plan with the client, allowing them to choose how far to pursue investigation. Provide written estimates before proceeding. Some clients may decline advanced diagnostics but accept a therapeutic trial with monitoring. Document these discussions clearly. The American Veterinary Medical Association practice resources offer guidance on client communication and financial planning in clinical practice.

How does my approach change when managing a suspected immune-mediated condition in a kitten under one year of age?

In young cats, infectious causes dominate the differential list. Feline leukemia virus, feline immunodeficiency virus, and infectious peritonitis can all produce clinical signs resembling immune-mediated disease. Test for retroviruses in every kitten before considering immunosuppressive therapy. Congenital immune defects, though uncommon, may present with recurrent or opportunistic infections instead of classic autoimmunity. The immune system of kittens is still maturing, and the balance between regulatory and effector pathways differs from adults. This developmental context influences both disease expression and response to immunomodulatory drugs. Consult current pediatric dosing references before prescribing, as metabolic pathways differ in young animals. The ACVIM consensus statements provide species-specific guidance applicable to juvenile patients.

What documentation should I maintain for a patient on long-term immunosuppressive therapy?

Maintain a problem list, medication log with start dates and dose adjustments, and a flow sheet tracking body weight, hematologic parameters, biochemistry values, and clinical signs at each visit. Record the rationale for each therapeutic decision, including the agent chosen, the dose prescribed, and the expected time to response. Note any adverse effects and their management. Document client communication, particularly discussions of prognosis, cost, and monitoring requirements. If glucocorticoids are used long term, track urine specific gravity, blood glucose, and body condition score. For practices using electronic records, consider a template that standardizes these parameters. The WOAH terrestrial animal health standards emphasize the importance of accurate record keeping in clinical practice.

How do I explain a presumptive immune-mediated diagnosis to a client who expects a definitive answer?

Acknowledge that veterinary medicine often relies on exclusion and response to therapy instead of a single confirmatory test. Explain that the diagnosis is based on the combination of clinical signs, laboratory findings, and exclusion of infectious and neoplastic mimics. Use an analogy such as a security system that overreacts to harmless signals, but emphasize that the underlying trigger is often unknown. Describe the treatment plan in terms of expected response and monitoring milestones. Be honest about uncertainty and about the possibility that the diagnosis may need revision if the response is incomplete. Provide written information the client can review at home. The MSD Veterinary Manual offers client-accessible summaries that can supplement your explanation.

When should I consider stopping immunosuppressive therapy, and how do I taper it safely?

Tapering decisions depend on the specific syndrome, the drug used, and the patient's response. Generally, once clinical signs have resolved and laboratory parameters have normalized for at least 4 to 8 weeks, a gradual dose reduction can begin. Reduce the dose by approximately 25 percent every 2 to 4 weeks while monitoring closely. If relapse occurs, return to the last effective dose and extend the maintenance period. Some cats require lifelong therapy at a low dose. Never stop glucocorticoids abruptly after prolonged use, as iatrogenic hypoadrenocorticism may result. The immunomodulatory drug review by Whitley and Day discusses rational usage and monitoring of immunosuppressive agents in small animal practice. Document each taper step and the patient's status at every recheck.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• Helminth-host immunological interactions: prevention and control of immune-mediated diseases.. 2012.
• Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics.. 2013.
• Multiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration.. 2016.
• Immunomodulatory drugs and their application to the management of canine immune-mediated disease.. 2011.
• Role of the Immune System in Diabetic Kidney Disease.. 2018.
• Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases.. 1998.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Canine Immune-Mediated Skin Disease: Diagnostic and Management Approach
• Canine Immune-Mediated Polyarthritis: Diagnostic Approach and Management
• Canine Immune-Mediated Myositis: Diagnostic and Therapeutic Approach
• Canine Immune-Mediated Arthropathy: Diagnostic and Management Framework
• Canine Immune-Mediated Hemolytic Anemia: Diagnostic and Management Framework

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.